成为最常见的原发性骨恶性肿瘤，骨肉瘤对生物标志物和治疗靶点进行深入研究以提高五年生存率迫切需要。采用单细胞RNA测序或大规模RNA测序的转录组分析已被用于检测各种癌症类型的生物标志物。我们应用Scissor结合了骨肉瘤的单细胞RNA测序数据和大规模转录组数据，提供细胞级别的信息和样本表型，以识别与生存相关的细胞亚群。通过研究生存相关的细胞亚群之间的差异，我们发现CCL21、CCL22、CCL24、CXCL11、CXCL12、CXCL13、GNAI2和RAC2在增殖细胞中与骨肉瘤患者预后显著相关。然后，我们基于细胞比例标准化的基因表达为每个样本分配了风险评分，并在公共数据集中进行了验证。本研究提供了临床见解，即增殖细胞中的趋化因子信号通路基因（CCL21、CCL22、CCL24、CXCL11、CXCL12、CXCL13、GNAI2和RAC2）可能是治疗骨肉瘤的潜在生物标志物。© 2023. BioMed Central有限公司，Springer Nature的一部分。

Osteosarcoma, as the most common primary bone malignancy, is urgent to be well-studied on the biomarkers and therapeutic targets to improve the five-year survival rate. Transcriptomic analysis using single-cell RNA or bulk RNA sequencing has been developed to detect biomarkers in various cancer types.We applied Scissor to combine single-cell RNA-seq data and bulk transcriptome data of osteosarcoma, providing cell-level information and sample phenotypes to identify the survival-associated cell subpopulations. By investigating the differences between the survival-associated cell subpopulations, we identified CCL21, CCL22, CCL24, CXCL11, CXCL12, CXCL13, GNAI2, and RAC2 in the proliferating cells that are significantly associated with osteosarcoma patient outcome. Then we assigned the risk score for each sample based on the cell proportion-normalized gene expression and validated it in the public dataset.This study provides the clinical insight that chemokine signaling pathway genes (CCL21, CCL22, CCL24, CXCL11, CXCL12, CXCL13, GNAI2, and RAC2) in proliferating cells might be the potential biomarkers for treatment of osteosarcoma.© 2023. BioMed Central Ltd., part of Springer Nature.